Pfizer Places Order For Shanxi Xintianyuan’s Pharmaceutical Intermediates
This article was originally published in PharmAsia News
Pfizer has officially placed a total order of RMB 100 million to purchase 500 tonnes of PCP per year from Shanxi Xintianyuan Pharm. & Chem. Shanxi Xintianyuan is one of Shanxi province's largest pharmaceutical intermediate manufacturers. The firm's main product, HO-EPCP, has secured a share of 30 percent, 40 percent and 85 percent in global, Asia and domestic market, respectively. Thanks to its high product quality, Shanxi Xintianyuan attracted the attention of Pfizer. Since last September, Pfizer has sent two groups of technical teams to conduct rigorous inspection of the firm and was satisfied with Shanxi Xintianyuan's technical standards as well as its soft and hard ware. (Click here for more - Chinese language)
You may also be interested in...
In a 1 June speech before the Alliance For a Stronger FDA, US FDA commissioner Stephen Hahn stressed the agency’s vigilance in guarding against consumer use of flawed COVID-19 products. He also made comments about the need for doctors to communicate more with patients. See what he said about the use of telehealth here.
Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’
Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity
‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.